Future prospects for Antimicrobial peptide development: peptidomimetics and antimicrobial combinations

Fecha de publicación

2026-02-17T08:36:49Z

2026-02-17T08:36:49Z

2021-02-24

2026-02-17T08:36:50Z



Resumen

Antimicrobial resistance is widely recognized as one of the major challenges of public health worldwide, as infections by multidrug-resistant (MDR) bacteria have reached worrisome levels. Three levels of antibiotic resistance have been described [Citation1]: i) multi-resistance (resistance to at least three different families of antimicrobials), ii) extreme resistance (resistance to all antimicrobials except colistin) and iii) pan-drug resistance (resistance to all available antimicrobials).

Tipo de documento

Artículo


Versión aceptada

Lengua

Inglés

Publicado por

Informa Healthcare

Documentos relacionados

Versió postprint del document publicat a: https://doi.org/10.1080/17460441.2021.1892072

Expert Opinion on Drug Discovery, 2021, vol. 16, num.6, p. 601-604

https://doi.org/10.1080/17460441.2021.1892072

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

(c) Informa Healthcare, 2021

Este ítem aparece en la(s) siguiente(s) colección(ones)